{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:12:10Z","timestamp":1791378730661,"version":"4.3.2"},"reference-count":24,"publisher":"MedWorks Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>This randomized, controlled trial examined the safety of clavulanic acid (CLAV), a GLT-1 (astrocytic glutamate transporter) modulator, in combination with intravenous cocaine to determine whether CLAV can be safely studied in outpatients with cocaine use disorder who may continue to use cocaine. Participants were adults with moderate to severe cocaine use disorder planning to continue regular cocaine use. In a placebo controlled, crossover, inpatient study, the safety of 3 doses of oral CLAV (250 mg\/day, 500 mg\/day, and added later 750 mg\/day) were studied in combination with 40 mg intravenous cocaine on a medical unit with close cardiac monitoring and pharmacokinetic sampling. Ten participants, 8 men and 2 women with cocaine use disorder, were studied with all participants receiving CLAV (250 mg, 500 mg, and placebo) and 5 participants receiving the additional 750 mg dose, in combination with cocaine. There were no clinically significant drug or dose related changes in vital signs, electrocardiogram intervals, pupillary diameters between CLAV and placebo. CLAV 500 mg decreased cocaine craving, using the 10 item Cocaine Craving Questionnaire-Brief, with a large effect size (Cohen\u2019s d = 1.25). Thirty-two mild to moderate adverse events were recorded, with most drug related events being gastrointestinal. CLAV, at the doses of 250 mg, 500 mg, and 750 mg was reasonably well tolerated and safe in combination with intravenous cocaine. Associated adverse events were mild to moderate and resolved. CLAV 500 mg was associated with decreased craving for cocaine in people with cocaine use disorder.<\/jats:p>","DOI":"10.64719\/pb.16587","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:16:27Z","timestamp":1773260187000},"page":"94-107","source":"Crossref","is-referenced-by-count":1,"title":["Clavulanic Acid Attenuated Cocaine Craving in Individuals with Cocaine Use Disorder"],"prefix":"10.64719","volume":"56","author":[{"given":"Mary F","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Ingre","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daohai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joya","family":"Maser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle M","family":"Kampman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D. Pharmacotherapy for cocaine use disorder\u2014a systematic review and meta-analysis. J Gen Intern Med. 2019;34(12):2858\u20132873.","DOI":"10.1007\/s11606-019-05074-8"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Post LA, Ciccarone D, Unick GJ et al. Decline in US drug overdose deaths by region, substance, and demographics. JAMA Netw Op. 2025;8(6):e2514997.","DOI":"10.1001\/jamanetworkopen.2025.14997"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Cano M, Salas-Wright CP, Oh S, Noel L, Hernandez D, Vaughn MG. Socioeconomic inequalities and Black\/White disparities in US cocaine-involved overdose mortality risk. Soc Psychiatry Psychiatr Epidemiol. 2022;57(10):2023\u20132035.","DOI":"10.1007\/s00127-022-02255-5"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Rawy M, Abdalla G, Look K. Polysubstance mortality trends in white and black americans during the opioid epidemic, 1999\u20132018. BMC Public Health. 2024;24(1):112.","DOI":"10.1186\/s12889-023-17563-x"},{"key":"ref5","unstructured":"Karch SB. Boca Raton. FL: CRC Press; 1993. Psychopathology of drug abuse."},{"key":"ref6","unstructured":"Richards JR, Le JK. StatPearls Publishing; Treasure Island, FL: 2023. Cocaine toxicity. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430976\/"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Maser J, Morrison MF, Khalid HP et al. Clavulanic acid-mediated increases in anterior cingulate glutamate levels are associated with decreased cocaine craving and brain network functional connectivity changes. Curr Ther Res. 2024;101:100751.","DOI":"10.1016\/j.curtheres.2024.100751"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Rothstein JD, Patel S, Regan MR et al. \u03b2-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433(7021):73\u201377.","DOI":"10.1038\/nature03180"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kim J, John J, Langford D, Walker E, Ward S, Rawls SM. Clavulanic acid enhances glutamate transporter subtype I (GLT-1) expression and decreases reinforcing efficacy of cocaine in mice. Amino Acids. 2016;48(3):689\u2013696.","DOI":"10.1007\/s00726-015-2117-8"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Philogene-Khalid HL, Morrison MF, Darbinian N, Selzer ME, Schroeder J, Rawls SM. The GLT-1 enhancer clavulanic acid suppresses cocaine place preference behavior and reduces GCPII activity and protein levels in the rat nucleus accumbens. Drug Alcohol Depend. 2022;232:109306.","DOI":"10.1016\/j.drugalcdep.2022.109306"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Bechard AR, Hamor PU, Wu L, Schwendt M, Knackstedt LA. The effects of clavulanic acid and amoxicillin on cue-primed reinstatement of cocaine seeking. Behav Neurosci. 2019;133(2):247.","DOI":"10.1037\/bne0000297"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Romach MK, Glue P, Kampman K et al. Attenuation of the euphoric effects of cocaine by the dopamine D1\/D5 antagonist ecopipam (SCH 39166) Arch Gen Psychiatry. 1999;56(12):1101\u20131106.","DOI":"10.1001\/archpsyc.56.12.1101"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Kost GC, Selvaraj S, Lee YB, Kim DJ, Ahn CH, Singh BB. Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking. Neurosci Lett. 2011;504(2):170\u2013175.","DOI":"10.1016\/j.neulet.2011.09.032"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Sanna F, Melis MR, Angioni L, Argiolas A. Clavulanic acid induces penile erection and yawning in male rats: comparison with apomorphine. Pharmacol Biochem and Behav. 2013;103(4):750\u2013755.","DOI":"10.1016\/j.pbb.2012.12.001"},{"key":"ref15","unstructured":"Nakagawa H, Yamada M, Tokiyoshi K, Miyawaki Y, Kanayama T. Penetration of potassium clavulanate\/ticarcillin sodium into cerebrospinal fluid in neurosurgical patients. Jpn J Antibiot. 1994;47(1):93\u2013101."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Saudagar PS, Survase SA, Singhal RS. Clavulanic acid: a review. Biotechnol Adv. 2008;26(4):335\u2013351.","DOI":"10.1016\/j.biotechadv.2008.03.002"},{"key":"ref17","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Stimulant use disorders: Developing drugs for treatment. [Accessed October 2025];2023 https:\/\/www.fda.gov\/media\/172703\/download."},{"key":"ref18","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatr. 1998;59(Suppl 20):22\u201333."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Sussner BD, Smelson DA, Rodrigues S, Kline A, Losonczy M, Ziedonis D. The validity and reliability of a brief measure of cocaine craving. Drug Alcohol Depend. 2006;83(3):233\u2013237.","DOI":"10.1016\/j.drugalcdep.2005.11.022"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Senn SS. Cross-over trials in clinical research. 2002 Aug 30; John Wiley & Sons.","DOI":"10.1002\/0470854596"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ferslew KE, Daigneault EA, Aten EM, Roseman JM. Pharmacokinetics and urinary excretion of clavulanic acid after oral administration of amoxicillin and potassium clavulanate. J Clin Pharmacol. 1984;24(10):452\u2013456.","DOI":"10.1002\/j.1552-4604.1984.tb01818.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Jeffcoat AR, Perez-Reyes MA, Hill JM, Sadler BM, Cook CE. Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. Drug Metab Dispos. 1989;17(2):153\u2013159.","DOI":"10.1016\/S0090-9556(25)08737-9"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Navarro AS. New formulations of amoxicillin\/clavulanic acid: a pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2005;44(11):1097\u20131115.","DOI":"10.2165\/00003088-200544110-00001"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Preston KL, Vahabzadeh M, Schmittner J, Lin JL, Gorelick DA, Epstein DH. Cocaine craving and use during daily life. Psychopharmacol. 2009;207(2):291\u2013301.","DOI":"10.1007\/s00213-009-1655-8"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:36:40Z","timestamp":1791315400000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/clavulanic-acid-attenuated-cocaine-craving-in-individuals-with-cocaine-use-disorder\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.16587","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}